(Q36773010)

16 August 2017

0 references

1 reference

title

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes (English)

1 reference

16 August 2017

Ali-Reza Golshayan

1

1 reference

16 August 2017

Tao Jin

2

1 reference

16 August 2017

Jaroslaw Maciejewski

3

1 reference

16 August 2017

Alex Z Fu

4

1 reference

16 August 2017

Boris Bershadsky

5

1 reference

16 August 2017

Michael W Kattan

6

1 reference

16 August 2017

Matt E Kalaycio

7

1 reference

16 August 2017

Mikkael A Sekeres

8

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

British Journal of Haematology

16 August 2017

published in

1 reference

16 August 2017

volume

137

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

125-132

1 reference

Proposals for the classification of the myelodysplastic syndromes

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06546.X

10.1111/J.1365-2141.2007.06546.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference